Autolus Shows Long Responses To CD19 CAR-T Therapy In Adult ALL Patients
Responses Longest With Low To Intermediate Tumor Burden
Autolus presented event-free survival rates and other updated results at ASH from its Phase Ib/II FELIX clinical trial of obe-cel, a CD19 CAR-T therapy recently submitted for US FDA approval.
